Paraneoplastic Neurological Syndromes are a set of degenerative autoimmune disorders due to the remote effects of cancer. Identification of a specific paraneoplastic antibody can guide the search for an underlying malignancy.
- Very useful biomarker for the detection of a cancer and a specific tumor type
- In many patients, the first signs of cancer manifest themselves with neurological dysfunction
- Immunotherapies aren’t very effective for paraneoplastic disorders
Early detection and quick treatment can make a difference in patient outcomes
“Patients with disorders of the CNS associated with autoantibodies can now be diagnosed and treated.”1 The positive identification of specific antibodies can help direct therapy to improve patient outcomes, avoid treatment that may harm the patient and/or aid in early detection and treatment of cancer.
In a majority of the paraneoplastic syndromes, the neurological symptoms appear before the cancer has been identified. Identification of paraneoplastic antibodies can direct the search for an underlying cancer and increase the likelihood of making an early diagnosis of the tumor and treating the neurological symptoms.
Other CNS Autoantibodies
Immunotherapy and other treatments have been successful in patients with antibodies against LGI1, CASPR2, VGKC, NMDA (NR1) and GAD65. Early detection may enable better outcomes.1
1Vincent A, Bien CG, Irani SR, Waters P. Autoantibodies associated with diseases of the CNS: new developments and future challenges. Lancet Neurol 2011; 10:559-72.